ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,317.59
-0.26%
Dow Jones
39,069.59
0.01%
Gold vs US Dollar
2,333.675
0.06%
Brent Oil
81.965
0.81%
Bitcoin
69,128.76
1.77%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSXV
  6. Essa Pharma Inc (EPI)

  7. Essa Pharma Inc (EPI) News

Essa Pharma (EPI)

Essa Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:TSXV:EPI
DateTimeSourceHeadlineSymbolCompany
25/02/202123:33PR Newswire (Canada)ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of ShareholdersTSXV:EPIEssa Pharma Inc
13/01/202112:00PR Newswire (Canada)ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castr...TSXV:EPIEssa Pharma Inc
15/12/202022:01PR Newswire (Canada)ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 20...TSXV:EPIEssa Pharma Inc
25/11/202012:00PR Newswire (Canada)ESSA Pharma to Participate at Evercore ISI 3rd Annual HealthCONx ConferenceTSXV:EPIEssa Pharma Inc
26/10/202021:01PR Newswire (Canada)ESSA Pharma Inc. Announces Delisting from the TSX-VTSXV:EPIEssa Pharma Inc
25/10/202000:18PR Newswire (Canada)ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR SymposiumTSXV:EPIEssa Pharma Inc
19/10/202012:00PR Newswire (Canada)ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific SymposiaTSXV:EPIEssa Pharma Inc
21/09/202012:00PR Newswire (Canada)ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech SummitTSXV:EPIEssa Pharma Inc
17/09/202022:05PR Newswire (Canada)ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020TSXV:EPIEssa Pharma Inc
14/09/202012:00PR Newswire (Canada)ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resist...TSXV:EPIEssa Pharma Inc
10/09/202012:00PR Newswire (Canada)ESSA Pharma to Participate in Multiple Upcoming Investor ConferencesTSXV:EPIEssa Pharma Inc
07/08/202001:00PR Newswire (Canada)ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020TSXV:EPIEssa Pharma Inc
31/07/202015:16PR Newswire (Canada)ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000TSXV:EPIEssa Pharma Inc
29/07/202014:07PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - EPITSXV:EPIEssa Pharma Inc
29/07/202014:05PR Newswire (Canada)IIROC Trading Resumption - EPITSXV:EPIEssa Pharma Inc
29/07/202002:18PR Newswire (Canada)ESSA Pharma Announces Pricing of Public Offering of Common SharesTSXV:EPIEssa Pharma Inc
28/07/202021:03PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - EPITSXV:EPIEssa Pharma Inc
28/07/202021:01PR Newswire (Canada)ESSA Pharma Announces Proposed Public Offering of Common SharesTSXV:EPIEssa Pharma Inc
28/07/202021:01PR Newswire (Canada)IIROC Trading Halt - EPITSXV:EPIEssa Pharma Inc
15/07/202012:00PR Newswire (Canada)ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostra...TSXV:EPIEssa Pharma Inc
22/06/202012:30PR Newswire (Canada)ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Me...TSXV:EPIEssa Pharma Inc
27/05/202012:00PR Newswire (Canada)ESSA Pharma to Present at Jefferies Virtual Healthcare ConferenceTSXV:EPIEssa Pharma Inc
15/05/202012:30PR Newswire (Canada)ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual MeetingTSXV:EPIEssa Pharma Inc
07/05/202022:05PR Newswire (Canada)ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020TSXV:EPIEssa Pharma Inc
30/04/202022:45PR Newswire (Canada)ESSA Pharma Announces FDA Allowance of the Clinical Investigation of EPI-7386 in Prostate CancerTSXV:EPIEssa Pharma Inc
13/04/202023:08PR Newswire (Canada)ESSA Pharma Enters into At-The-Market Equity Offering Sales AgreementTSXV:EPIEssa Pharma Inc
31/03/202012:00PR Newswire (Canada)ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business UpdateTSXV:EPIEssa Pharma Inc
28/02/202000:51PR Newswire (Canada)ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of ShareholdersTSXV:EPIEssa Pharma Inc
13/02/202022:48PR Newswire (Canada)ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019TSXV:EPIEssa Pharma Inc
10/02/202023:15PR Newswire (Canada)ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific SymposiaTSXV:EPIEssa Pharma Inc
 Showing the most relevant articles for your search:TSXV:EPI

Your Recent History

LSE
BP.
Bp
LSE
NG.
National Grid
LSE
POS
Plexus
LSE
VAST
Vast Resources
LSE
AAZ
Anglo Asian Mining
LSE
BIRD
Blackbird
LSE
TERN
Tern
LSE
SCE
Surface Transforms
LSE
SCLP
Scancell
LSE
GDR
Genedrive
LSE
ZED
Zenova
LSE
BOO
Boohoo
LSE
TEK
Tekcapital
LSE
LLOY
Lloyds Banking
LSE
KEFI
Kefi Gold And Copper
LSE
GKP
Gulf Keystone Petroleum
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved